EFSA’s 2025 CBD Safety Statement: Setting a New Pace for Novel Foods in Europe

The European Food Safety Authority (EFSA) released a pivotal update on September 8, 2025, sharpening its stance on cannabidiol (CBD) safety as a novel food (EFSA source). This high-profile move directly impacts ongoing and future applications for CBD products seeking novel food status across the European Union (EU) in 2026 and beyond. The new attention to rigorous dose-response profiles, impurities, and long-term effects creates a demanding new regulatory bar for industry stakeholders, from ingredient manufacturers to supplement brands.

Below, we detail what has changed, EFSA’s key concerns, and—importantly—actionable recommendations for applicants navigating this evolving compliance terrain.

Key Points from the 2025 EFSA CBD Update

New and Persistent Safety Concerns

EFSA’s preparatory work reiterates and expands on unresolved concerns around CBD’s safety profile, including:

• Liver toxicity and elevated liver enzymes
• Endocrine disruption potential
• Reproductive and developmental toxicity
• Neurodevelopmental impacts (especially concerning vulnerable and pediatric populations)
• Bioaccumulation and variability in bioavailability, which influence dose and effect

Significantly, the 2025 statement highlights the lack of robust dose–response data and insufficient information on product impurities and degradation products—crucial for both synthetic and plant-derived CBD.

EFSA’s panel proposes an extremely low provisional safe daily intake of 2 mg per day for adults, and reiterates no established safe use for those under 25, pregnant or breastfeeding women, or those concurrently using other medications (NutraIngredients, 2025).

The 2025 Data Gaps: Implications for CBD Novel Food Dossiers

1. Specifications & Stability for Different Product Types

• CBD Isolate vs. Broad-/Full-Spectrum Extracts:
• Applicant dossiers must provide detailed product specifications, including batch-to-batch impurity profiles and stability data under storage and use conditions.
• There is rising expectation for genetic, chemical, and contaminant consistency—beyond merely meeting ‘isolate’ labeling claims.

2. NOAEL (No Observed Adverse Effect Level) Derivation

• Submissions now require high-quality, peer-reviewed studies demonstrating a clear NOAEL for the specific formulation and delivery matrix.
• Dose-response data across species, careful attention to accumulation, and data on repeated use are demanded.

3. Vulnerable Populations Exclusion

• All 2026 and later applications must strictly exclude data extrapolated to children, young adults (under 25), pregnant or breastfeeding women, and those on medications.
• Labeling and marketing restrictions will likely be necessary as a result.

4. Impurities and Degradation Product Assessment

• Both synthetic and botanical preparations must be characterized for heavy metals, residual solvents, pesticide residues, and new impurity classes.
• Long-term stability and shelf-life studies must measure both active ingredient retention and breakdown by-products.

5. Longitudinal Adverse Event Reporting (AER) Plans

• Post-market monitoring will be critical: applicants must supply adverse event reporting frameworks and commit to sharing updated toxicity, hepatotoxicity, and neurotoxicity data as it emerges.
• Expect enforcement bodies to scrutinize response to real-world adverse event data closely.

6. Pharmacokinetics & Matrix Effects

• New data show delivery method and food matrix significantly influence absorption and systemic levels (EFSA, 2025). Dossiers should include bioavailability studies in realistic conditions.

Action List for CBD Novel Food Applicants in 2026

To maximize authorization chances under the new regime, applicants should:

• Update product specifications with full impurity characterizations and batch stability data.
• Secure robust NOAEL data from recent long-term studies; ensure method and matrix alignment to EU uses.
• Exclude vulnerable population claims and data; prepare compliant labeling and marketing strategies.
• Develop ongoing AER frameworks and cooperate with EU/Member State vigilance agencies after market entry.
• Adapt to a lower provisional maximum daily dose—formulations above 2 mg/day may require significant justification.
• Work with validated contract labs for stability, bioavailability, and degradation studies under EU-relevant storage and use conditions.
• Monitor future EFSA consultations and guidance updates, as 2026 will likely bring further refinement.

National Enforcement, Divergence, and the UK FSA Comparison

EFSA’s Position vs. FSA (UK)

While the UK’s Food Standards Agency (FSA) operates its own pathway outside the EU, the EFSA’s more conservative approach is influencing stakeholder sentiment across Europe. As of autumn 2025, the FSA was reviewing major CBD novel food applications and continues a risk-based—but sometimes more pragmatic—stance (FSA source). However, UK dossiers still require:

• Comprehensive stability, toxicity, and impurity data (mirroring many new EFSA demands)
• Restrictive labeling for children, pregnant/lactating women, and those on medications
• National guidance on maximum daily amount is similarly cautious

EU Member State Enforcement Variability

Despite EU-wide novel food legislation, enforcement of CBD rules still varies across Member States. Some—like Germany and Austria—take a zero-tolerance approach for non-authorized CBD foods, with frequent recalls and fines. Others may tolerate limited retail pending EU-level decisions, but the window for this ‘grey area’ is closing rapidly under the new EFSA guidance.

• Expect product recalls, border seizures, and stepped-up lab testing in the leadup to and following new authorizations.
• Retailers and brands trading across borders must maintain documentation, compliance records, and labeling that align with both local and EFSA rules.

Key Takeaways for Businesses and Stakeholders

EFSA’s 2025 safety statement signals an era of greatly heightened scrutiny for novel food CBD products in the EU. The regulatory risk for rushing to market without comprehensive specification, stability, impurity, and NOAEL data is sharply increasing.

• Thorough, science-backed dossiers are now the floor, not the ceiling, for market access.
• Ignoring adverse event reporting or vulnerable population restrictions is likely to lead to rapid enforcement actions, recalls, and legal liability.
• UK pathway offers modestly more regulatory flexibility, but transparency and robust safety data are non-negotiable.

Ongoing vigilance and responsive compliance programs will be critical for success in the 2026 novel food landscape.

For trusted, real-time updates on EFSA CBD safety 2025 novel foods, best-practice dossier support, and a compliance partner across EU and UK jurisdictions, visit CannabisRegulations.ai.